Institutional Implementation: Setting Up Tarlatamab Administration

Opinion
Video

Panelists discuss how the administration of tarlatamab requires thorough pretreatment screening, staff training, and close monitoring for immune-related adverse effects such as cytokine release syndrome, emphasizing the importance of patient education, rapid intervention, and specialized infrastructure for safe and effective treatment.

Summary for Physicians:

Protocol for Tarlatamab Administration:

  • Site Setup:
  • Pretreatment screening: Ensure patients meet eligibility, assess organ function, and check for contraindications.

  • Staff training: Ensure all staff are trained on administration protocols and handling potential toxicities.

  • Monitoring: Patients are monitored for immune-related adverse effects such as cytokine release syndrome (CRS), especially during the first dose.

Challenges:

  • Management of CRS:
  • Need for rapid intervention and close monitoring in case of severe reactions.
  • Patient Education:
  • Ensuring patients understand potential adverse effects and the importance of timely reporting.
  • Infrastructure:

Need for specialized facilities and equipment for infusion and monitoring, especially in the event of adverse reactions.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
2 experts in this video
2 experts in this video
2 experts are featured in this series.
2 experts are featured in this series.
4 experts in this video
2 experts in this video
Related Content